![Andrew Sinclair](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andrew Sinclair
Directeur/Membre du Conseil chez
ADICET BIO, INC.
Fortune : 6 368 $ au 30/06/2026
Profil
Andrew Sinclair is currently an Independent Director at Adicet Bio, Inc. since 2021.
Dr. Sinclair is a Director at Entact Bio Ltd., Entact Bio, Inc., and Timberlyne Therapeutics, Inc. Dr. Sinclair is a Portfolio Manager & Partner at Abingworth Management Ltd. since 2008 and Head of Publics & Late Stage at Abingworth LLP since 2008.
Dr. Sinclair is a Member of The Institute of Chartered Accountants in England & Wales.
Formerly, Dr. Sinclair was an Independent Director at Sierra Oncology, Inc. from 2019 to 2022.
Dr. Sinclair was a Director at HSBC Global Markets Select Funds Plc.
Dr. Sinclair was a Director at Abingworth Bioventures VI LP from 2016 to 2020.
Dr. Sinclair was an Independent Non-Executive Director at Verona Pharma Ltd. Dr. Sinclair was an Independent Director at Soleno Therapeutics, Inc. from 2018 to 2026.
Dr. Sinclair was a Research Analyst at Credit Suisse Securities (Europe) Ltd. Dr. Sinclair was a Research Analyst at HSBC Bank Plc (Broker) from 2007 to 2008.
Dr. Sinclair completed undergraduate education at King's College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ADICET BIO INC 0,01 % | 21/06/2026 | 737 ( 0,01 % ) | 6 368 $ | 30/06/2026 |
Postes actifs de Andrew Sinclair
| Sociétés | Poste | Début |
|---|---|---|
| ADICET BIO, INC. | Directeur/Membre du Conseil | 02/03/2021 |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Analyste en capital-investissement | 25/11/2008 |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Operates as an investment firm | Corporate Officer/Principal | 01/01/2008 |
Institute of Chartered Accountants in England & Wales
 Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services Offers accountancy qualifications and world class business resources | Corporate Officer/Principal | - |
Locki Therapeutics Ltd.
 Locki Therapeutics Ltd. BiotechnologyHealth Technology Develops cancer immune therapy | Directeur/Membre du Conseil | 04/11/2021 |
Entact Bio, Inc.
 Entact Bio, Inc. BiotechnologyHealth Technology Develops medicines for increasing protein function | Directeur/Membre du Conseil | - |
Anciens postes connus de Andrew Sinclair
| Sociétés | Poste | Fin |
|---|---|---|
| SOLENO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 15/05/2026 |
| SIERRA ONCOLOGY, INC. | Directeur/Membre du Conseil | 01/07/2022 |
Abingworth Bioventures VI LP
 Abingworth Bioventures VI LP Investment ManagersFinance Acts as Venture Capital Fund | Directeur/Membre du Conseil | 01/01/2020 |
| ░░░░ ░░░░ ░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Andrew Sinclair
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
60
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases | Health Technology |
Soleno Therapeutics, Inc.
 Soleno Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes novel therapeutics for the treatment of rare diseases | Health Technology |
HSBC Global Markets Select Funds Plc
 HSBC Global Markets Select Funds Plc Investment Trusts/Mutual FundsMiscellaneous Acts as Open-End Investment Fund/Unit Trust | Miscellaneous |
Abingworth Management Ltd.
Abingworth Management Ltd. Investment ManagersFinance Operates as an investment firm | Finance |
Abingworth Bioventures VI LP
Abingworth Bioventures VI LP Investment ManagersFinance Acts as Venture Capital Fund | Finance |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Finance |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services Offers accountancy qualifications and world class business resources | Commercial Services |
Credit Suisse Securities (Europe) Ltd.
 Credit Suisse Securities (Europe) Ltd. Investment Banks/BrokersFinance Provides brokerage services | Finance |
HSBC Bank Plc (Broker)
 HSBC Bank Plc (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Verona Pharma Plc
 Verona Pharma Plc Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of allergic rhinitis and other chronic respiratory diseases | Health Technology |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adicet Bio, Inc.
 Adicet Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the development of cell immunotherapies | Health Technology |
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Develops cancer immune therapy | Health Technology |
Entact Bio, Inc.
Entact Bio, Inc. BiotechnologyHealth Technology Develops medicines for increasing protein function | Health Technology |
Choisissez Zonebourse 
